A breakthrough discovery

The discovery of HAMLET defines a new class of cancer drugs with broad effects against cancers of different origin and a high degree of selectivity. HAMLET’s aim is to prove the efficacy of HAMLET therapy and to develop drugs that kill tumour cells with greater precision than current drugs.

This is a game-changing discovery for potential cancer treatments for the future. To have been leading this project is something that I am very proud of and I am entirely grateful to all my team members, who have been working tirelessly, to get where we are today – in a position of being ready to create a new drug,

Catharina SvanborgChairman of the Board/Founder

Board and Executive Team

Catharina Svanborg

Chairman of the Board

Catharina Svanborg received her MD in 1974 and Ph.D. in 1978 and has been the Professor of Clinical Immunology at Lund University since 1989. In 1996, Svanborg was elected Fellow of the Royal Swedish Academy of Science. Her research is extremely influential, with strong international networks. From 1979 to 1980, Svanborg was a visiting Professor at Imperial College and from 2008 to 2010, she was Principal Investigator at the Singapore Immunology Network. Her awards include the Domagk award, the non-restricted grant award (BMS), the Kennedy Visiting Professorship Award at Imperial College, London, the Edwin H. Beachey Distinguished Visiting Professorship Award at the University of Tennessee, the Jubilee Award of the Swedish Medical Society, the Nordic Söderberg Award and the Scientist of the Year Award, 2014. Svanborg has published more than four-hundred papers and mentored some forty-five graduate students, as well as several postdoctoral fellows who now pursue successful careers..

Bengt Westermark

Director

Bengt Westermark is Senior Professor of Tumour Biology at Uppsala University. From 1996 to 2002, Westermark was Dean of the Faculty of Medicine and from 1999 to 2002 he was the Vice Principal for Medicine and Pharmacy at University. He has received numerous awards and honors, such as The Swedish Society of Medicine’s Jubilee Prize, The Fernströms Nordic Prize, The Farber Award, The Lennox K Black Prize, and The Acta Endocrinologica Award. In 2013, Westermar was awarded The King’s Gold Medal, and is a member of The Royal Swedish Academy of Sciences, The Royal Society of Sciences and of The European Molecular Biology Organization.

Helena Lomberg

Director

Doctor of Medicine, University of Gothenburg, 1986. Dr. Lomberg specializes in the clinical development of pharmaceuticals focused on clinical studies. Lomberg has over twenty years of senior management experience in international companies such as GlaxoWelcome, Bayer, NMCT, and Quintiles. Since 2008, Helena Lomberg runs her own company, BCT Consulting, and works primarily as a consultant for smaller biotech companies and conducts clinical trials.

Christer Köhler

Director

Christer Köhler has extensive experience in the global pharmaceutical industries, including Roche and AstraZeneca. Köhler was recently Vice President and Global Head of CNS and Pain Research Areas, as well as Global Director of Discovery Research within AstraZeneca. Köhler is now an advisor to various investment groups, private investors, biotech/pharmaceutical companies, and other life science companies. Other Company Commitments: Le Care AB; co-founder and chairman. KyNexis LLC; co-founder and chairman. Papilly AB (publ); board member. Intidyn LLC; board.

Mats Persson

CEO

Mats Persson is a molecular biologist by training and received his Ph.D. in 1991. He developed a broad knowledge of Drug Development and has held several senior positions within R&D. He was a member of the R&D leadership team at LEO Pharma in Denmark where he was responsible for external R&D collaborations including academic partnerships and commercial alliances. Persson has more than twenty years of experience in clinical research and development at AstraZeneca and from development projects in clinical phases I through IV.
14
million
new cancer cases each year
25
million
cases within the next two decades
1.
trillion
cost of cancer in the US in 2010
1
deaths are due to cancer